rs61752123
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000318.3(PEX2):c.355C>T(p.Arg119*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000743 in 1,614,056 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000085 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000073 ( 0 hom. )
Consequence
PEX2
NM_000318.3 stop_gained
NM_000318.3 stop_gained
Scores
2
2
3
Clinical Significance
Conservation
PhyloP100: 2.32
Genes affected
PEX2 (HGNC:9717): (peroxisomal biogenesis factor 2) This gene encodes an integral peroxisomal membrane protein required for peroxisome biogenesis. The protein is thought to be involved in peroxisomal matrix protein import. Mutations in this gene result in one form of Zellweger syndrome and infantile Refsum disease. Alternative splicing results in multiple transcript variants encoding the same protein. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.613 CDS is truncated, and there are 1 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 8-76983824-G-A is Pathogenic according to our data. Variant chr8-76983824-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 13704.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-76983824-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PEX2 | NM_000318.3 | c.355C>T | p.Arg119* | stop_gained | 4/4 | ENST00000357039.9 | NP_000309.2 | |
PEX2 | NM_001079867.2 | c.355C>T | p.Arg119* | stop_gained | 3/3 | NP_001073336.2 | ||
PEX2 | NM_001172086.2 | c.355C>T | p.Arg119* | stop_gained | 5/5 | NP_001165557.2 | ||
PEX2 | NM_001172087.2 | c.355C>T | p.Arg119* | stop_gained | 3/3 | NP_001165558.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PEX2 | ENST00000357039.9 | c.355C>T | p.Arg119* | stop_gained | 4/4 | 1 | NM_000318.3 | ENSP00000349543.4 | ||
PEX2 | ENST00000522527.5 | c.355C>T | p.Arg119* | stop_gained | 3/3 | 1 | ENSP00000428638.1 | |||
PEX2 | ENST00000520103.5 | c.355C>T | p.Arg119* | stop_gained | 3/3 | 2 | ENSP00000428590.1 | |||
PEX2 | ENST00000518986.5 | c.355C>T | p.Arg119* | stop_gained | 3/3 | 3 | ENSP00000429304.1 |
Frequencies
GnomAD3 genomes AF: 0.0000855 AC: 13AN: 152072Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
13
AN:
152072
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000143 AC: 36AN: 251402Hom.: 0 AF XY: 0.000125 AC XY: 17AN XY: 135868
GnomAD3 exomes
AF:
AC:
36
AN:
251402
Hom.:
AF XY:
AC XY:
17
AN XY:
135868
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000732 AC: 107AN: 1461864Hom.: 0 Cov.: 35 AF XY: 0.0000798 AC XY: 58AN XY: 727222
GnomAD4 exome
AF:
AC:
107
AN:
1461864
Hom.:
Cov.:
35
AF XY:
AC XY:
58
AN XY:
727222
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152192Hom.: 0 Cov.: 32 AF XY: 0.000134 AC XY: 10AN XY: 74404
GnomAD4 genome
AF:
AC:
13
AN:
152192
Hom.:
Cov.:
32
AF XY:
AC XY:
10
AN XY:
74404
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
17
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Peroxisome biogenesis disorder 5A (Zellweger) Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 07, 2024 | This sequence change creates a premature translational stop signal (p.Arg119*) in the PEX2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 187 amino acid(s) of the PEX2 protein. This variant is present in population databases (rs61752123, gnomAD 0.3%). This premature translational stop signal has been observed in individual(s) with Zellweger spectrum disorders (PMID: 1546315, 7681622, 9452066, 9585609, 10528859, 15542397, 21465523, 23430938). ClinVar contains an entry for this variant (Variation ID: 13704). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 26, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 26, 2019 | NM_000318.2(PEX2):c.355C>T(R119*) is classified as pathogenic in the context of peroxisome biogenesis disorder type 5. Sources cited for classification include the following: PMID 15542397, 1546315 and 14630978. Classification of NM_000318.2(PEX2):c.355C>T(R119*) is based on the following criteria: The variant causes a premature termination codon that is not expected to be targeted by nonsense-mediated mRNA decay; however, literature evidence strongly supports pathogenicity. Please note: this variant was assessed in the context of healthy population screening. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Jun 10, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 27, 2023 | - - |
Peroxisome biogenesis disorder 5B Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Aug 16, 2016 | - - |
Zellweger spectrum disorders Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Peroxisome biogenesis disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 31, 2017 | Variant summary: The PEX2 c.355C>T (p.Arg119X) variant results in a premature termination codon, predicted to cause a truncated or absent PEX2 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant was found in the large control database ExAC and control cohorts in the literature at a frequency of 0.0002708 (34/125548 control chromosomes), which does not exceed the estimated maximal expected allele frequency of a pathogenic PEX2 variant (0.001118). Several publications have cited the variant in patients with diagnoses that are confirmed with standard biochemical tests. Additionally, a functional study demonstrated a lack of peroxisome formation via immunofluorescence in cultured fibroblasts of a patient who was homozygous for the variant of interest (Imamura_AJHG_1998). Furthermore, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
PEX2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 10, 2024 | The PEX2 c.355C>T variant is predicted to result in premature protein termination (p.Arg119*). This variant has been reported in the homozygous and compound heterozygous states in several individuals with Zellweger syndrome (Steinberg et al. 2004. PubMed ID: 15542397; Ebberink et al. 2011. PubMed ID: 21031596; Shimozawa et al. 1999. PubMed: 10528859). This variant is reported in 0.24% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. Nonsense variants in PEX2 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Peroxisome biogenesis disorder 5B;C3553940:Peroxisome biogenesis disorder 5A (Zellweger) Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 30, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at